Format

Send to

Choose Destination
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Dec 28;42(12):1389-1394. doi: 10.11817/j.issn.1672-7347.2017.12.006.

[Metformin reduces plasma triglycerides in ob/ob obese mice via inhibiting the hepatic apoA5 expression].

[Article in Chinese; Abstract available in Chinese from the publisher]

Author information

1
Department of Cardiovascular Medicine, Second Xiangya Hospital, 
Central South University, Changsha 410011, China initialhxs@163.com.
2
Department of Stomatology, Second Xiangya Hospital, 
Central South University, Changsha 410011, China.
3
Department of Cardiovascular Medicine, Second Xiangya Hospital, 
Central South University, Changsha 410011, China.

Abstract

in English, Chinese

To investigate the role of apolipoprotein A5 (apoA5) in the pathogenesis of obesity-related hypertriglyceridemia and the related therapeutic effects of metformin.
 Methods: The ob/ob mice were treated with regular chow diet and metformin for 4 weeks, and the levels of hepatic triglyceride (TG) and apoA5 were measured. Hepatic IAR20 cells were treated with metformin and/or apoA5 siRNAs, and then cellular TG contents and apoA5 expression were determined.
 Results: High plasma and hepatic levels of apoA5 and TG were found in ob/ob mice. The plasma levels of apoA5 were positively correlated with plasma TG in these mice. Metformin could dose-dependently decrease the plasma and hepatic levels of apoA5 and TG in ob/ob mice. Metformin could also dose-dependently reduce cellular TG contents and apoA5 expression, these effects were attenuated by knockdown of apoA5.
 Conclusion: Hepatic apoA5 is up-regulated in ob/ob mice, which contributes to the elevation of plasma TG. Metformin could inhibit hepatic apoA5 expression, leading to the reduction of the plasma level of TG.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for CENTRAL SOUTH UNIVERSITY
Loading ...
Support Center